MTOR and pachyonychia congenita: Here, we showed that gemcitabine can sensitize the in vitro and in vivo efficacies of Oba01 by synergistically enhancing Oba01-induced PARP-dependent apoptosis, suppressing the cell cycle, and suppressing the PI3K/mTOR pathway activation in various PC models (Fig. 8).